Flamel Technologies

Flamel Ireland Limited

Imedex

Exela Sterile Medicines LLC

Avadel Legacy Pharmaceuticals, LLC

Alain Constancis

Gauthier Pouliquen

Jill Simpson

Pierre Danner

Angela Sutterer

Olivier Soula

Cécile Bonnet-Gonnet

Gerard Soula

Jean-Louis Tayot

Remi Meyrueix

Rémi Meyrueix

Florence Nicolas

David Chognot

Ge/ Rard Soula

Je/ Ro/ Tiollier

Cécile Bonnet Gonnet

Cysteine compositions comprising less than about 400 &#x3bc;g/L of aluminum. For example, solutions of cysteine comprising a pharmaceutically acceptable solvent, cysteine, and less than about 145 &#x3bc;g/L of aluminum, wherein the solution is devoid of visible particulate matter. Cysteine compositions described herein may be suitable for injection. For example, disclosed cysteine solutions may be provided intravenously to meet amino acid nutritional requirement in individuals receiving total parenteral nutrition. Also provided are processes for preparing cysteine compositions, and methods for providing cysteine to individuals in need thereof.

Cysteine composition and injection

The present invention relates to novel pharmaceutical formulations based on aqueous colloidal suspensions for the prolonged release of one or more active principles, and to the applications, especially therapeutic applications, of these formulations. Formulations may include an aqueous colloidal suspension of low viscosity based on micrometric particles of a water-soluble, biodegradable, amphiphilic polymer carrying hydrophobic groups and ionizable hydrophilic groups that are at least partially ionized, said particles being capable of associating spontaneously and non-covalently with an active principle, at pH=7.0, under isotonic conditions. This suspension contains multivalent ions of opposite polarity to that of the hydrophilic groups, the ratio r, defined by the formula r=n&#xd7;([IM]/[GI]), where n is the valency of said multivalent ions, [IM] is the molar concentration of multivalent ions, [GI] is the molar concentration of ionizable groups GI, being between 0.3 and 10.

Pharmaceutical formulations for the prolonged release of active principle(s), and their applications, especially therapeutic applications

The invention relates to injectable long-acting insulin formulations for the treatment of types I and II diabetes in humans and animals. The essential object of the invention is to provide an injectable long-acting insulin formulation in the form of a colloidal suspension which is stable, which has a good local tolerance and toxicity compatible with the chronic treatment of diabetics, and which maintains a substantial hypoglycemic effect extending over at least 24 hours after a single administration, e.g. by the subcutaneous route. To achieve this object, the invention relates to a stable aqueous colloidal formulation of insulin-laden nanoparticles of at least one poly(Leu-block-Glu) in which the pH is between 5.8 and 7.0, the osmolarity O (in mOsmol) . . . : 270&#x2266;O&#x2266;800, and the viscosity v (in mPa&#xb7;s) is low, namely v&#x2266;40. The nanoparticles of poly(Leu-block-Glu) have a mean hydrodynamic diameter Dh such that: 15&#x2266;Dh&#x2266;40. The invention relates to an antidiabetic drug based on this long-acting insulin formulation and injectable using needles of gauge 29 G, 30 G or 31 G.

Long-acting colloidal insulin formulation and its preparation

The aim of the invention is to provide a modified collagen peptide for preventing post-operative adhesions that is non-toxic, economic, in addition to being easy to obtain, sterilize, manipulate and implement, having controlled biodegradability and presenting a sufficiently strong initial mechanical resistance in situ (cohesion). This is achieved in the case of the modified collagen peptide for preventing post-operative adhesions according to the invention which is characterized in that it comprises at least one collagen peptide that is modified by grafting thiol functions that are free or substituted, cross-linkable and/or at least partly cross-linked, whereby the thiol functions are provided by mercaptoamine radicals that are exclusively grafted on the aspartic and glutamic acids of the collagen chains by means of amide bonds. The modified collagen peptide can exist in the form of a homogeneous or composite film, as a gel or in as a liquid which can be applied and cross-linked per se as on in vivo tissue.

Cross-linked collagenic peptide for preventing post-surgical adhesions

Organic products containing reactive thiol functions, one method for

The invention relates to an adhesive, biocompatible, biodegradable and non-toxic composition for surgical use, in particular for binding tissues, which composition is of the following general formula: ##STR1## in which: R is a hydrocarbon chain containing from 1 to 50 carbon atoms,

Adhesive compositions for surgical use

Growing community of inventors

Lyons, France

Alain Constancis